https://orcid.org/0000-0003-0490-4421
Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Hala H. Halawah, Nimer S. Alkhatib, Abdulaali R. Almutairi, Mohammad Saleh, Shiraz S. Halloush, Omar Rashdan, Lama Masadh, Osama H. Abusara & Ivo Abraham. (2023) Cost-efficiency analysis and expanded treatment access modeling of conversion to rituximab biosimilars from reference rituximab in Jordan. Journal of Medical Economics 26:1, pages 835-842.
Read now
Read now
Consuela Cheriece Yousef, Mansoor Ahmed Khan, Hind Almodaimegh, Majed Alshamrani, Meteb Al-Foheidi, Hana AlAbdalkarim, Ahmed AlJedai, Anjum Naeem & Ivo Abraham. (2023) Cost-efficiency analysis of conversion to biosimilar filgrastim for supportive cancer care and resultant expanded access analysis to supportive care and early-stage HER2+ breast cancer treatment in Saudi Arabia: simulation study. Journal of Medical Economics 26:1, pages 394-402.
Read now
Read now
Nimer S Alkhatib, Shiraz Halloush & Ivo Abraham. (2023) The status and preparation for the next decade of biosimilars in the Middle Eastern and North African region. Expert Opinion on Biological Therapy 23:8, pages 671-677.
Read now
Read now
Ali McBride, Karen MacDonald, Adolfo Fuentes-Alburo & Ivo Abraham. (2021) Cost-efficiency and expanded access modeling of conversion to biosimilar trastuzumab-dkst with or without pertuzumab in metastatic breast cancer. Journal of Medical Economics 24:1, pages 743-756.
Read now
Read now
Ali McBride, Karen MacDonald, Adolfo Fuentes-Alburo & Ivo Abraham. (2021) Conversion from pegfilgrastim with on-body injector to pegfilgrastim-jmdb: cost-efficiency analysis and budget-neutral expanded access to prophylaxis and treatment. Journal of Medical Economics 24:1, pages 598-606.
Read now
Read now
Articles from other publishers (8)
Sherin Ismail, Laila Abu Esba, Mansoor Khan, Hana Al-Abdulkarim, Hind Modimagh & Consuela Yousef. (2022) An Institutional Guide for Formulary Decisions of Biosimilars. Hospital Pharmacy 58:1, pages 38-48.
Crossref
Crossref
Sophia Z. Humphreys, Robert B. Geller & Paul Walden. (2022) Pegfilgrastim Biosimilars in US Supportive Oncology: A Narrative Review of Administration Options and Economic Considerations to Maximize Patient Benefit. Oncology and Therapy 10:2, pages 351-361.
Crossref
Crossref
Seenu M. Hariprasad, Richard P. Gale, Christina Y. Weng, Hans C. Ebbers, Mourad F. Rezk & Ramin Tadayoni. (2022) An Introduction to Biosimilars for the Treatment of Retinal Diseases: A Narrative Review. Ophthalmology and Therapy 11:3, pages 959-982.
Crossref
Crossref
Paul Cornes, John Kelton, Rongzhe Liu, Omer Zaidi, Jennifer Stephens & Jingyan Yang. (2022) Real-world cost–effectiveness of primary prophylaxis with G-CSF biosimilars in patients at intermediate/high risk of febrile neutropenia. Future Oncology 18:16.
Crossref
Crossref
Ali McBride, Neda Alrawashdh, Karen MacDonald & Ivo Abraham. (2022) Expanded access to anticancer treatments from conversion to biosimilar pegfilgrastim-cbqv in US breast cancer patients. Future Oncology 18:3, pages 363-373.
Crossref
Crossref
Karen MacDonald, Neda Alrawashdh, Ali McBride & Ivo Abraham. (2021) Conversion to biosimilar pegfilgrastim-cbqv enables budget-neutral access to FOLFIRINOX treatment for metastatic pancreatic cancer. Future Oncology 17:33, pages 4561-4570.
Crossref
Crossref
Florian Scotte, Hélène Simon, Philippe Laplaige, Eric-Charles Antoine, Caroline Spasojevic, Nathalie Texier, Karine Gouhier & Christos Chouaid. (2021) Febrile neutropenia prophylaxis, G-CSF physician preferences: discrete-choice experiment. BMJ Supportive & Palliative Care, pages bmjspcare-2021-003082.
Crossref
Crossref
Barbara Finck, Robert B. Geller & Paul Walden. (2021) Letter to the Editor Regarding “The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence”. Advances in Therapy 38:6, pages 3483-3486.
Crossref
Crossref